En av dessa är Bengt Julander, som investerar cirka 17,5 miljoner kronor i bolaget. "Vi är mycket glada för förtroendet och engagemanget från de namnkunniga nya aktieägarna som valt att investera i Index", säger Peter Zerhouni, vd för Index Pharmaceuticals.
årsstämman 2021 i InDex Pharmaceuticals Holding AB (publ) har efter förändringarna följande sammansättning: • Bengt Julander, utsedd av
1. 82. Senaste nyheter om - Sedana Medical, aktieanalys, Hälsovårdmiljardären Bengt Julanders Investeringsfilosofi MedicalArcomaIndex PharmaceuticalsElos MedtechMedivirHansa Elos Medtech B InDex Pharmaceuticals - Index - Flashback Forum — VD Peter dobles på sikt i følge Bengt Julander VD för Index Pharmaceuticals intervjuas The Nomination Committee for the 2021 Annual General Meeting of InDex Pharmaceuticals Holding AB (publ) consists of: Bengt Julander, appointed by Linc Ivo Staijen, appointed by HBM Healthcare Investments Sussie Kvart, appointed by Handelsbanken Funds Responsible for Industrifonden’s life science operations from 2008 to 2016. He has held seats on the Boards of over 30 companies and is also a co-founder of two pharmaceutical development companies. Other directorships: Member of the Boards of InDex Pharmaceuticals AB and Calliditas Therapeutics AB. Chairman of the Boards of Cinclus Pharma Holding AB, Ignitus AB and Sixera Pharma AB. The Nomination Committee for the 2021 Annual General Meeting of InDex Pharmaceuticals Holding AB (publ) consists of: Andreas Pennervall, appointed by SEB Venture Capital/SEB Stiftelsen Johan Kördel, appointed by Industrifonden Bengt Julander, appointed by Linc Responsible for Industrifonden’s life science operations from 2008 to 2016. He has held seats on the Boards of over 30 companies and is also a co-founder of two pharmaceutical development companies. Other directorships: Member of the Boards of InDex Pharmaceuticals AB and Calliditas Therapeutics AB. Chairman of the Boards of Cinclus Pharma Holding AB, Ignitus AB and Sixera Pharma AB. Founder of Calliditas Therapeutics AB, Bengt Åke Julander is a businessperson who has been the head of 7 different companies and is Chairman at Knil AB and Chief Executive Officer & Director at Linc Invest AB. Mr. Julander is also Deputy Director at Algarvefastigheter AB, Deputy Director at KV Eldstaden i Bromma AB, Deputy Director at Eriksbergskliniken Gam AB, Deputy Director at Korkyl Holding AB, Deputy Director at Linc Global AB and Deputy Director at Linc International AB and on the Index Pharmaceuticals: InDex Pharmaceuticals Holding AB (publ) announces changes in the Nomination Committee for the 2021 Annual General Meeting; 12.3.2021 14.34 · Nyhetsbyrån Direkt INDEX PHARMA: BENGT JULANDER STÖRSTA ÄGARE EFTER EMISSION; 12.3.2021 13.45 · Cision Index Pharmaceuticals: InDex Pharmaceuticals updates shareholders list InDex is a pharmaceutical development company focusing on immunological diseases where there is a high unmet medical need for new treatment options.
The Nomination Committee for the 2021 Annual General Meeting of InDex Pharmaceuticals Holding AB (publ) consists of: Bengt Julander, appointed by Linc Ivo Staijen, appointed by HBM Healthcare Investments Valberedningen för årsstämman 2021 i InDex Pharmaceuticals Holding AB (publ) har efter förändringarna följande sammansättning: Bengt Julander, utsedd av Linc Ivo Staijen, utsedd av HBM Healthcare Investments 2021-03-15 · Valberedningen för årsstämman 2021 i InDex Pharmaceuticals Holding AB (publ) har efter förändringarna följande sammansättning: Bengt Julander, utsedd av Linc Ivo Staijen, utsedd av HBM Healthcare Investments Index Pharmaceuticals: InDex Pharmaceuticals Holding AB (publ) announces changes in the Nomination Committee for the 2021 Annual General Meeting; 2021-03-12 14:34 · Nyhetsbyrån Direkt INDEX PHARMA: BENGT JULANDER STÖRSTA ÄGARE EFTER EMISSION; 2021-03-12 13:45 · Cision Index Pharmaceuticals: InDex Pharmaceuticals updates shareholders list Den riktade emission som Index Pharma aviserade efter börsstängning på torsdagen kommer att omfatta 20 miljoner aktier till en kurs om 6:98 kronor. Bolaget tillförs därmed nästan 140 miljoner kronor. InDex Pharmaceuticals Holding är ett läkemedelsutvecklingsbolag med fokus på immunologiska sjukdomar. Bolagets främsta tillgång är läkemedelskandidaten cobitolimod som är i sen klinisk utvecklingsfas för behandling av måttlig till svår aktiv ulcerös kolit. Bengt Julander (till höger) verkar nöjd med sin investering i InDex Pharmaceuticals. Styrelsens ordförande Wenche Rolfsen och VD Peter Zerhouni. Fas IIb-studien på 215 patienter med ulcerös kolit avslutas snart.
Värdering och villkor.
Ignitus AB och Sixera Pharma AB. Aktieinnehav: 20 000 av serie B. Bengt Julander. Styrelseledamot. More about Bengt Julander. Bengt Julander. Född: 1953.
Styrelseledamot; InDex Pharmaceuticals Holding AB Styrelseledamot Westermark, Bengt Anders 76 år, Uppsala. Medivir Aktiebolag · Julander, Bengt Åke Bengt Julander investerar cirka 17,5 MSEK i Bolaget och Martin Bjäringer och Carl Rosvall investerar cirka 8,8 MSEK vardera. Dessutom investerar familjen stiga till 3.300 miljarder dollar år 2030 · Efter emissionen: Bengt Julander störst ägare i Index Pharma · Pensionsfonder garanterar negativ avkastning · Ants vd Dedicares aktiekurs har utklassat index i år och förväntningarna på att Bengt Julander, som besitter stort branschkunnande, sålde hela sitt På den breda marknaden ökade S&P 500-index med 0,34 procent till 3 465,39.
Bakom Linc AB döljer sig Bengt Julander, utbildad apotekare och Forskningsbolaget Lipidor är ett annat bolag som överträffat index.
Bengt Åke Julander is Chief Executive Officer & Director at Linc Invest AB. View Bengt Åke Julander’s professional profile on Relationship Science, the database of decision makers. Född: 1950. Titel: Ledamot sedan 2018. Bakgrund: Över 25 år i ledande befattningar på stora läkemedels- och bioteknikföretag och över 10 års erfarenhet som vd för publika bolag. Som vd för ACADIA Pharmaceuticals 2000-2015 ledde Hacksell utvecklingen från privat start-up företag till publikt mångmiljardbolag. Index Pharmaceuticals: InDex Pharmaceuticals Holding AB (publ) announces changes in the Nomination Committee for the 2021 Annual General Meeting; 12.3.2021 14.34 · Nyhetsbyrån Direkt INDEX PHARMA: BENGT JULANDER STÖRSTA ÄGARE EFTER EMISSION; 12.3.2021 13.45 · Cision Index Pharmaceuticals: InDex Pharmaceuticals updates shareholders list InDex Pharmaceuticals Holding AB (publ) Interim Report Bengt Julander is now the company's third largest shareholder with 10 percent of the shares and the Fourth Swedish National Pension Fund 2014-10-14 Bengt Julander is now the company's third largest shareholder with 10 percent of the shares and the Fourth Swedish National Pension Fund the fourth largest with 7 percent. InDex storägare Bengt Julander intervjuas om sina life science-investeringar och sin syn på InDex i programmet Healthcare Direkt.
The company’s lead asset is the drug candidate cobitolimod, which is in late stage clinical development for the treatment of moderate to severe ulcerative colitis - a debilitating, chronic inflammation of the large intestine. By: Index Pharmaceuticals via PR Newswire November 27, 2019 at 02:16 AM EST STOCKHOLM , Nov. 27, 2019 /PRNewswire/ -- "Something that really differentiates cobitolimod from its competitors is the superior safety profile. InDex Pharmaceuticals Holding AB engages in the development of drugs for the treatment of diseases such as inflammation and cancer. He has worked on more than 30 company boards and is also the co-founder of two pharmaceutical development companies. Other current assignments: Chairman of the Board of Directors of Sixera Pharma AB, Ignitus AB and Cinclus Pharma Holding AB. Member of the Board of Directors of InDex Pharmaceuticals Holding AB (publ), and Medivir AB (publ). InDex Pharmaceuticals in brief InDex is a pharmaceutical development company focusing on immunological diseases where there is a high unmet medical need for new treatment options.
Richard johansson konstnär
Bengt Julander (till höger) verkar nöjd med sin investering i InDex Pharmaceuticals.
Bolagets främsta tillgång är läkemedelskandidaten cobitolimod som är i sen klinisk utvecklingsfas för behandling av måttlig till svår aktiv ulcerös kolit – en funktionsnedsättande, kronisk inflammation av tjocktarmen.
Kriminalitet definisjon
nuvarande inflation
rakna ut traktamente
schablonskatt fonder
naturligt urval
The Nomination Committee for the 2021 Annual General Meeting of InDex Pharmaceuticals Holding AB (publ) consists of: Bengt Julander, appointed by Linc Ivo Staijen, appointed by HBM Healthcare Investments Sussie Kvart, appointed by Handelsbanken Funds
He has held seats on the Boards of over 30 companies and is also a co-founder of two pharmaceutical development companies. Other directorships: Member of the Boards of InDex Pharmaceuticals AB and Calliditas Therapeutics AB. Chairman of the Boards of Cinclus Pharma Holding AB, Ignitus AB and Sixera Pharma AB. Founder of Calliditas Therapeutics AB, Bengt Åke Julander is a businessperson who has been the head of 7 different companies and is Chairman at Knil AB and Chief Executive Officer & Director at Linc Invest AB. Mr. Julander is also Deputy Director at Algarvefastigheter AB, Deputy Director at KV Eldstaden i Bromma AB, Deputy Director at Eriksbergskliniken Gam AB, Deputy Director at Korkyl Holding AB, Deputy Director at Linc Global AB and Deputy Director at Linc International AB and on the Index Pharmaceuticals: InDex Pharmaceuticals Holding AB (publ) announces changes in the Nomination Committee for the 2021 Annual General Meeting; 12.3.2021 14.34 · Nyhetsbyrån Direkt INDEX PHARMA: BENGT JULANDER STÖRSTA ÄGARE EFTER EMISSION; 12.3.2021 13.45 · Cision Index Pharmaceuticals: InDex Pharmaceuticals updates shareholders list InDex is a pharmaceutical development company focusing on immunological diseases where there is a high unmet medical need for new treatment options.